Breaking Finance News

Zacks Investment Research announced Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), raising its target price to $5.00 today

Having a price of $4.51, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) traded -1.10% lower on the day. With the last close down -4.28% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. GLMD has recorded a 50-day average of $4.16 and a two hundred day average of $4.71. Trade Volume was down over the average, with 19,848 shares of GLMD changing hands under the typical 84,497

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) had its target price raised to $5.00 by Zacks Investment Research in a report released Wednesday October 05, 2016. The new target price indicates a possible upside of 0.11% from the company's previous close.

On 08/01/2016, Maxim Group released a statement on Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) dropped the target price from $24.00 to $9.00 that suggested an upside of 1.10%.

Recent Performance Chart

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd has with a one year low of $3.50 and a one year high of $10.20 and has a market capitalization of $0.

A total of 5 analysts have released a report on Galmed Pharmaceuticals Ltd. One equity analyst rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $18.20.

Brief Synopsis On Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *